Literature DB >> 10880821

Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine.

J P Heaton1.   

Abstract

Central nervous system processes are fundamental to sexual function. Considerable progress has been made in our understanding of the neuroanatomical and neuropharmacological bases for erection. Based largely on rat models, there is adequate understanding presently of the general anatomical areas of the brain that relate to sexual function, including the medial amygdala, medial preoptic area, paraventricular nucleus, the periaqueductal gray, ventral tegmentum and others. There is also a burgeoning body of evidence implicating nitric oxide, dopamine, serotonin and oxytocin as critical central neurotransmitters involved in various aspects of sexual function. The role of dopamine, in particular, appears fundamental in the mediation of erectile responses in both animals and man. Additionally, clinical research with apomorphine, a D1/D2 agonist, has shown significant promise in improving erections in men with a wide range of erectile difficulties. Finally, a new classification matrix has been proposed for existing treatments for erectile dysfunction based upon the putative site and mechanism of action. Implications for the further development of neuropharmacological agents in this area are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880821     DOI: 10.1016/s0149-7634(00)00023-3

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  14 in total

Review 1.  Romantic love: a mammalian brain system for mate choice.

Authors:  Helen E Fisher; Arthur Aron; Lucy L Brown
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-12-29       Impact factor: 6.237

Review 2.  Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans.

Authors:  Tillmann H C Krüger; Uwe Hartmann; Manfred Schedlowski
Journal:  World J Urol       Date:  2005-05-12       Impact factor: 4.226

3.  Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension.

Authors:  I F Hussain; C M Brady; M J Swinn; C J Mathias; C J Fowler
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

Review 4.  The future is today: emerging drugs for the treatment of erectile dysfunction.

Authors:  Maarten Albersen; Alan W Shindel; Kuwong B Mwamukonda; Tom F Lue
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

Review 5.  Dopamine, Erectile Function and Male Sexual Behavior from the Past to the Present: A Review.

Authors:  Maria Rosaria Melis; Fabrizio Sanna; Antonio Argiolas
Journal:  Brain Sci       Date:  2022-06-24

6.  Erectile function and risk of Parkinson's disease.

Authors:  Xiang Gao; Honglei Chen; Michael A Schwarzschild; Dale B Glasser; Giancarlo Logroscino; Eric B Rimm; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2007-09-17       Impact factor: 4.897

7.  The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury.

Authors:  H Kim; D W Sohn; S D Kim; S-H Hong; H J Suh; C B Lee; S W Kim
Journal:  Int J Impot Res       Date:  2010-09-23       Impact factor: 2.896

Review 8.  Disorders of ejaculation.

Authors:  E A Jannini; C Simonelli; A Lenzi
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

9.  Anabolic steroids have long-lasting effects on male social behaviors.

Authors:  Kaliris Y Salas-Ramirez; Pamela R Montalto; Cheryl L Sisk
Journal:  Behav Brain Res       Date:  2009-12-30       Impact factor: 3.332

10.  Homeostatic mechanisms in dopamine synthesis and release: a mathematical model.

Authors:  Janet A Best; H Frederik Nijhout; Michael C Reed
Journal:  Theor Biol Med Model       Date:  2009-09-10       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.